

Poster Presentations: Illuminating Public Health Protection



1



2

Poster Presentations: Illuminating Public Health Protection

Financial Disclosures

Nathan Siegel declares that he has a current affiliation or financial arrangement as an employee of The Christ Hospital Health Network and as founder of Community Pharmacy AI Solutions within the past 24 months.

All of the other presenters declare that they do not have a current affiliation or financial arrangement with any ineligible companies that may have a direct interest in the subject matter of this continuing pharmacy education (CPE) activity within the past 24 months.

Additionally, NABP staff involved in the planning of this activity do not have a current affiliation or financial arrangement with any ineligible companies that may have a direct interest in the subject matter of NABP's CPE Program within the past 24 months.

All relevant financial disclosures have been mitigated.

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

NABP®

3

Q&A

You may use the Q&A tool on your screen to submit questions to the presenters.

After each presentation, our host will read the questions out loud
in the order they are received.

Our presenters will also answer questions via the Q&A tool.

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

NABP®

4



Strengthening Public Health Protection Through Interprofessional Transitions of Care

Bre-Anna Lyn
PharmD Candidate, Class of 2026
Nova Southeastern University
Barry and Judy Silverman College of Pharmacy

Tricia Gangoo-Dookhan, PharmD
Clinical Assistant Professor
Nova Southeastern University
Barry and Judy Silverman College of Pharmacy

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

5

Strengthening Public Health Protection Through Interprofessional Transitions of Care

Presenters:

Bre-Anna Lyn, PharmD Candidate, Class of 2026
Tricia Gangoo-Dookhan, PharmD, CPh (Faculty Advisor)

6

FINANCIAL DISCLOSURES

- Tricia Gangoo-Dookhan, PharmD, CPh, Clinical Assistant Professor, and Bre-Anna Lyn, PharmD Candidate, Class of 2026, declare that we have not had an affiliation or financial agreement with any ineligible companies within the past 24 months.

7

LEARNING OBJECTIVES

- Describe how interprofessional collaboration and interprofessional education improve transitions of care (TOC) and reduce preventable hospital readmissions.
- Identify key social determinants of health including health literacy, medication access, food insecurity, and transportation, that impact post-discharge outcomes.
- Discuss the impact of enhanced TOC interventions on 30-day hospital readmissions and adherence to primary care physician follow-up visits.


8

BACKGROUND


- Hospital readmissions create significant financial and clinical burdens, costing over \$41 billion nationally.
- Social determinants of health, including transportation, food insecurity, low health literacy, and medication access barriers, contribute to poor transitions of care (TOC) and preventable readmissions.
- Interprofessional transitional care interventions involving pharmacy and medical students may improve continuity of care, reduce readmissions, and increase primary care follow-up adherence.

9


METHODS



10



11



12

CONCLUSION

- A university-based call-center model engaged pharmacy and medical students in addressing SDOH barriers during multidisciplinary TOC calls and strengthen IPC/IPE skills, which showed clinically meaningful, though not statistically significant, trends toward improved PCP follow-up and reduced readmissions.
- Outcomes were limited by a small, single-site sample, language restrictions, and variable engagement; broader, multi-center studies with longer follow-up and objective adherence/safety measures are needed to validate and scale this model.

13

SELF ASSESSMENT QUESTION

1. Which SDOH barrier was most commonly identified in this study?
 - a. Transportation
 - b. Food insecurity
 - c. Medication access
 - d. Health literacy

14

SELF ASSESSMENT QUESTION

2. Why is transition of care considered a critical period for intervention?
- a. Patients are fully stabilized
 - b. No risk for medication errors
 - c. High risk for readmissions and adverse events
 - d. Limited need for follow-up care

15

SELF ASSESSMENT QUESTION

3. What primary outcome was evaluated in this study?
- a. Medication cost reduction
 - b. 30-day hospital readmissions and PCP follow-up adherence
 - c. Emergency department visits only
 - d. Insurance enrollment

16

REFERENCES



17

CONTACT INFORMATION

Tricia Gangoo-Doohkan, PharmD, CPh, Clinical Assistant Professor (Advisor)
Email: tg4@nova.edu

Bre-Anna Lyn, Doctor of Pharmacy Candidate (Presenter)
Email: bl1116@mynsu.nova.edu

18



NABP
National Association of
Boards of Pharmacy

An Emerging Threat: Medetomidine- Adulterated Fentanyl and Gaps in Overdose Response Systems

Mansi Saxena
BS Candidate, Class of 2027
Nova Southeastern University
Barry and Judy Silverman College of Pharmacy

Tricia Gangoo-Dookhan, PharmD
Clinical Assistant Professor
Nova Southeastern University
Barry and Judy Silverman College of Pharmacy

Zachariah Dookhan
BS Candidate, Class of 2027
Nova Southeastern University
Barry and Judy Silverman College of Pharmacy

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

19

An Emerging Threat: Medetomidine- Adulterated Fentanyl and Gaps in Overdose Response Systems

Presented by:

Mansi Saxena, BS Candidate, Class of 2027, Dr. Kiran Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL

Zachariah Dookhan, AA, BS Candidate, Class of 2027, Halmos College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, FL



NSU
Florida
Barry and Judy Silverman
College of Pharmacy
NOVA SOUTHEASTERN
UNIVERSITY

20

June 2026

Other Contributors

Co-Authors:

Katherine Dookhan, BS Candidate, Class of 2026, Nova Southeastern University, Fort Lauderdale, FL

Mahi Desai, BS Candidate, Class of 2026, Nova Southeastern University, Fort Lauderdale, FL

Faculty Advisors:

Tricia Gangoo-Dookhan, PharmD, CPh, Faculty, Barry & Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL

Robert C. Speth, PhD, Faculty, Barry & Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL

21

June 2026

Financial Disclosures

Mansi Saxena and Zachariah Dookhan declare that they do not hold a current affiliation or financial arrangement with any ineligible organization in the past 24 months.

22

June 2026

Learning Objectives

1. Describe the emergence of medetomidine as a fentanyl adulterant and its impact on overdose.
2. Recognize management challenges and gaps in treating medetomidine toxicity and withdrawal.

23

June 2026

Background

- The opioid crisis in the United States continues to evolve into a complex polysubstance epidemic with a shift toward medetomidine, a more potent α_2 adrenergic agonist.
- Medetomidine produces prolonged sedation and cardiovascular instability that are not reversed by naloxone.
- Clinicians are required to adapt recognition and management strategies and highlight the growing importance of pharmacists and public health professionals in harm reduction response.

24

June 2026	
Methodology	
• Literature Review	Study Design
• PubMed, Google Scholar, and CDC Reports • Focusing on literature between 2020 and 2025	Data Sources
• Medetomidine • Xylazine • Alpha 2 adrenergic agonist • Fentanyl adulterants • Polysubstance overdose • Opioid toxicity • Withdrawal syndromes	Key Words

25

June 2026	
Results	
• Pharmacology ◦ Medetomidine is a Potent $\alpha 2$ adrenergic agonist suppressing norepinephrine release ◦ More potent and selective than xylazine ◦ Prolonged central nervous system depression • Clinical Effects ◦ Profound sedation, respiratory depression, bradycardia, hypotension, and delayed recovery ◦ Incomplete response to naloxone	

26

June 2026

Results


- **Management**

- No FDA-approved reversal agent
- Limited detection on standard toxicology screens.
- Currently, only symptomatic management of severe withdrawal symptoms
- Minimize withdrawal severity with mild $\alpha 2$ agonist drugs, eg, clonidine
- Continue to monitor the patient and redose with the mild $\alpha 2$ agonist if needed

- **Public Health**

- Increasing presence in illicit drug supply
- Highlights the need for improved surveillance, expanded toxicology testing, and drug checking programs
- Need to educate EMTs and ED personnel about dangers of medetomidine in drug overdose patients

27



28

June 2026

Discussion & Conclusion

- Shift towards a more potent non-opioid adulterant highlights the current limitations in overdose recognition and management
- Effects of non-opioid adulterants are not reversed by naloxone, increasing clinical risk
- Atypical presentations challenge clinicians, pharmacists, and public health officials to better recognize opioid vs. non-opioid overdose symptoms

29

June 2026

Future Implications

- Addressing the shift towards more potent nonopioid adulterants requires improved surveillance methods, including:
 - Expanded toxicology screenings
 - Broader implementation of drug-checking programs
 - Development of standardized clinical guidelines
- Public health stands to educate the community and promote policy change:
 - Targeted intervention
 - Naloxone distribution
 - Regular oversight of emerging adulterants

30

June 2026

Self-Assessment Questions

1. Why should clinicians, pharmacists, and public health officials alike be concerned about the increased use of medetomidine in the illicit drug supply?
 - a. Medetomidine is fully responsive to naloxone, representing little clinical urgency
 - b. Medetomidine carries a lower overdose risk in comparison to its opioid counterparts
 - c. Medetomidine is not commonly available and is not prescribed for pain management
 - d. Medetomidine contributed to atypical overdose patterns representing broader management challenges

31

June 2026

Self-Assessment Questions

2. Countering the emergence of polysubstance use in the United States is a growing concern only for physicians.
 - a. True
 - b. False

32

June 2026

References



33

June 2026

Thank You

For your attention

Mansi Saxena

ms5443@mynsu.nova.edu

(410) 440 - 1159

Zachariah Dookhan

zd116@mynsu.nova.edu

(754) 301 - 0780

34



From Viral to Vulnerable: Illuminating Public Health Risks of Social Media-Driven Medication and Supplement Misinformation

Revaa Goyal
PharmD and MBA Candidate, Class of 2027
University of Rhode Island College of Pharmacy

Kristina E. Ward, PharmD, BCPS
Clinical Professor, Chair of Pharmacy Practice, and
Director of Drug Information Services
University of Rhode Island College of Pharmacy

Anna Carlino
PharmD and MBA Candidate, Class of 2027
University of Rhode Island College of Pharmacy

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

35



From Viral to Vulnerable: Assessing the Public Health Risks of Social Media-Driven Medication & Supplement Misinformation

Anna Carlino and Revaa Goyal, PharmD and MBA Candidates,
Class of 2027, University of Rhode Island College of Pharmacy

Kristina E. Ward, PharmD, BCPS,
Clinical Professor, Chair of Pharmacy Practice, and Director of Drug Information Services,
University of Rhode Island College of Pharmacy

36

Disclosures

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

Anna Carlino, Revaa Goyal, and Kristina Ward declare that they have not had an affiliation or financial relationship with any organization that may have a direct interest in the subject matter of this CPE activity in the past 24 months.

No AI disclosures.

37

Learning Objectives

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

After viewing this presentation, learners should be able to:

- Recognize common patterns of viral posts that contain medication and supplement misinformation on social media platforms.
- Discuss pharmacist and board of pharmacy-level strategies that support public health protection against medication and supplement misinformation.
- Identify features of social media content that signal reliable versus unreliable or potentially harmful health claims.
- Summarize how social media can both support and undermine patient engagement in health care decision-making.

38

Why Social Media Misinformation Matters

Purpose: Social media has become a major source of health information for patients. While online platforms may increase awareness and encourage health care engagement, viral medication and supplement content can blur the line between wellness messaging and evidence-based medical guidance.

Main Concerns:

- Unsafe self-treatment
- Delayed medical care
- Drug supplement interactions
- Reduced trust in health care professionals

```
graph LR; A[Viral Claim] --> B[Patient Decision]; B --> C[Potential Harm]
```

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

39


Background & Significance

Social media is a leading source of health information for the public. However, misinformation about medications and supplements is widespread and can lead to harmful health behaviors.


- Up to 87% of health related posts on Twitter (X) contain misinformation
- Health misinformation is most prevalent in topics related to smoking products, drugs (opioids, marijuana), and vaccines
- Misinformation undermines public health efforts and is exacerbated by social and economic inequalities
- Social media platforms enable “pseudoexperts and nonexpert influencers” to amplify misleading health content

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

40



41



42

Patient & Public Health Risks

**Delayed Diagnosis or Treatment**

Reliance on wellness content may postpone appropriate medical care

**Adverse Effects**

Improper use, high doses, or prolonged use can cause harm

**Drug-Supplement Interactions**

Can reduce efficacy or increase toxicity

**Financial Harm**

Consumers may purchase ineffective or misleading products

**Reduced Trust & Engagement**

Misinformation can decrease reliance on health care professional and evidence based care

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

43

Social Media Benefits Vs. Risk

Risks

- Algorithms prioritize engagement, not accuracy
- Lacks individual content (age, conditions, medications)
- Oversimplifies credibility on the basis of popularity, not expertise
- Anecdotes mistaken for evidence

Benefits

- First point of exposure to health topics
- Increase awareness & symptom recognition
- Reduce stigma & encourages open conversations
- Encourages patients to ask better questions at visits
- Short-form content can make complex topics more accessible

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

44

The Pharmacist Response Framework

THE UNIVERSITY OF RHODE ISLAND COLLEGE OF PHARMACY

Ask



Invite the patient to explain what they saw and what they are considering

Explain



Use plain language to clarify evidence, risks, interactions, and safer options

Teach Back



Ask the patient to repeat the plan in their own words to confirm understanding

45

Opportunities for Public Health Protection

THE UNIVERSITY OF RHODE ISLAND COLLEGE OF PHARMACY

Normalize “What did you see online?” conversations

- This shifts counseling from reactive to proactive. Patients may not volunteer that TikTok, Instagram, or a wellness influencer influenced their decision unless directly asked.

Use de-identified pharmacy observations to identify emerging misinformation trends

- Track recurring misinformation themes seen in pharmacy practice, such as “natural Ozempic,” “natural Adderall,” cortisol protocols, parasite cleanses, or medication replacement claims.

Establish referral triggers for high-risk misinformation

- Define escalation triggers for prescriber or urgent care referral, poison control consultation, or FDA adverse event reporting

Create point-of-care claim-check content

- Use QR-linked, pharmacist-reviewed micro-messages to address common viral claims where patients make decisions: pharmacy counters, vaccine areas, MTM visits, and digital pharmacy pages

46

Regulatory Considerations

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

Support public health protection without policing social media

- Encourage routine screening for supplements, wellness protocols, and products patients found online

Develop guidance documents & public education initiatives

- Develop pharmacist and patient resources for responding to viral health claims

Collaborate with public health agencies & consumer protection

- Coordinate with public health, FDA, FTC, and consumer protection partners when claims become misleading or unsafe

Address policy gaps: lack of standardized response to viral misinformation and unclear line between wellness marketing & medical claims

- Clarify the boundary between wellness marketing and medical claims, including cure, treatment, replacement, or guaranteed-result language

47

Key Takeaways



Social media can inform, but it can also mislead patients about medications and supplements.



Viral wellness claims often blur the line between marketing and evidence-based medical advice.



Misinformation may lead to delayed treatment, adverse effects, drug interactions, and financial harm.



Pharmacists play a critical role in identifying misinformation and guiding safe patient decisions.



Open conversation and teach-back strategies improve patient understanding and trust.

48

Self Assessment Question #1

Which approach best supports public health protection while preserving patient engagement when a patient asks about a viral supplement claim seen on social media?

- A. Advise the patient to avoid all health information on social media
- B. Review the claim with the patient using credible sources and encourage social media to be used as a conversation starter, not a treatment plan
- C. Recommend trying the product first if it is widely discussed online
- D. Refer the patient to online testimonials to compare experiences

49

Self Assessment Question #2

Which statement in a social media post most strongly suggests misleading supplement information?

- A. It explains that supplements may interact with medications
- B. It distinguishes personal experience from general medical guidance
- C. It promotes a product as “natural and therefore safe” without discussing adverse effects or interactions
- D. It advises viewers to verify claims with credible sources

50

Poster Presentations: Illuminating Public Health Protection

References

1. Basch CH, Meleo-Erwin Z, Fera J, Jaime C, Basch CE. The potential role of pharmacists in counteracting health misinformation in social media. *Res Social Adm Pharm.* 2022;18(8):3272-3278. doi:10.1016/j.sapharm.2022.03.002
2. Amerson AB, Nalwa K. Pharmacists must combat mis/disinformation! *Res Social Adm Pharm.* 2021;17(7):1332-1333. doi:10.1016/j.sapharm.2020.12.013
3. Wang Y, McKee M, Torbica A, Stuckler D. Prevalence of health misinformation on social media—challenges and mitigation before, during, and beyond the COVID-19 pandemic: scoping literature review. *J Med Internet Res.* 2024;26:e38786. doi:10.2196/38786
4. International Pharmaceutical Federation (FIP). *Health Literacy and Patient Safety: Pharmacists' Role.* International Pharmaceutical Federation; 2023.
5. National Academies of Sciences, Engineering, and Medicine. *Health Literacy in the Context of Misinformation and Disinformation Workshop.* National Academies Press; 2023.
6. Centers for Disease Control and Prevention. Organizations and committees related to health literacy. Accessed May 10, 2026. <https://www.cdc.gov/healthliteracy/>
7. Vaccine Confidence Project. Monitoring vaccine confidence and misinformation. Accessed May 10, 2026. <https://www.vaccineconfidence.org/>
8. ScienceUpFirst. Countering health misinformation through evidence-based science communication. Accessed May 10, 2026. <https://www.scienceupfirst.com/>
9. Healthcare Information For All (HIFA). Improving global access to reliable healthcare information. Accessed May 10, 2026. <https://www.hifa.org/>
10. Accreditation Council for Pharmacy Education. Continuing pharmacy education resources on misinformation and health communication. Accessed May 10, 2026. <https://www.acpe-accredit.org/>
11. Agency for Healthcare Research and Quality. Use the teach-back method: tool #5. TeamSTEPS® 2.0 curriculum tools and materials. Accessed May 11, 2026. <https://www.ahrq.gov/teamsteps-program/curriculum/communication/tools/teachback.html>

51



Anna Carlino, PharmD/MBA Candidate, Class of 2027
Email: annacarlino@uri.edu
Phone: (603) 395-0686
LinkedIn: www.linkedin.com/in/annacarlino



Revaa Goyal, PharmD/MBA Candidate, Class of 2027
Email: rgoyal@uri.edu
Phone: (719) 492-9030
LinkedIn: www.linkedin.com/in/revaaagoyal

THE
UNIVERSITY
OF RHODE ISLAND
COLLEGE OF
PHARMACY

52

Questions?
Thank you!

53



Shining Light on Hidden Risks: How Pharmacists Can Illuminate Artificial Intelligence Transparency and Protect Public Health

Nicole J. Asal, PharmD, BCPS
Clinical Associate Professor
University of Rhode Island College of Pharmacy

Nathan Siegel, PharmD
Founder and Principal Investigator
Community Pharmacy AI Solutions

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

54

Shining Light on Hidden Risks: How Pharmacists Can Illuminate Artificial Intelligence Transparency and Protect Public Health

Nicole J. Asal, PharmD, BPCS

The University of Rhode Island, College of Pharmacy

Nathan Siegel, PharmD

Community Pharmacy AI Solutions

55

Disclosures

Dr Asal declares that she does not have/have not had an affiliation or financial arrangement with any ineligible companies within the past 24 months.

Dr Siegel declares that he has a current affiliation or financial arrangement as an employee of The Christ Hospital Health Network and as founder of Community Pharmacy AI Solutions within the past 24 months.

56

Background

Patients are increasingly using artificial intelligence (AI) for medication and health information; however, pharmacists often lack guidance on how these platforms are developed, how they perform with health-related data, and how to counsel patients on its AI reliability.

57

Objectives

- Objectives
 - Describe at least three transparency limitations of ChatGPT, Claude, Gemini, and Perplexity that affect the reliability of artificial intelligence (AI)-generated health information.
 - Recall how each AI tool handles source attribution and retrieval and why this matters for evaluating health care information.
 - List three failure modes associated with consumer-facing AI models (i.e., ChatGPT, Claude, Gemini, and Perplexity) based on a novel scoring tool.
 - Outline key concepts related to AI transparency and tool performance.
 - Identify strategies for counseling patients on AI-generated health and medication information.

58

Methods

- This pilot study completed a mixed methods systematic comparative analysis of four major AI platforms (ie, ChatGPT, Claude, Gemini, and Perplexity) regarding transparency and responses to 10 medication safety scenarios using a novel scoring tool.
- Reviewed publicly available materials from each platform’s website and industry reporting sources compare transparency features such as model architecture, training data information, source attribution, and privacy.
- Submitted 10 medication-related questions to each platform and assessed overall safety of responses using a 9-item rubric.

59

Results

Table 1. Abbreviated Transparency Report

Dimension	Generalized Findings
Model architecture	All platforms are minimally transparent on architecture
Training data	Limited disclosure across all products
Source attribution	Perplexity highest, ChatGPT lowest
Algorithmic Transparency	All platforms are minimally transparent; proprietary
Overall transparency	Claude and Perplexity rated higher (in different ways), ChatGPT and Gemini rated moderate-to-low No platforms are HIPAA-compliant; data retained
Patient privacy	Most platforms (ChatGPT, Gemini, Perplexity) are opt-out by default



Questions asked to AI platforms

60

Results

Figure 1. Platform Query Safety Score Matrix


	Q1 Warfarin +Fluconazole	Q2 Paxlovid +Verapamil	Q3 Lithium Toxicity	Q4 Ibuprofen +Lisinopril	Q5 Lisinopril Demographics	Q6 Nexavarin Hallucination	Q7 UTI/Preg /Bactrim	Q8 Expired EpiPen	Q9 Hidden APAP OD	Q10 Benadryl +Alcohol
ChatGPT	13	17	18	20	22	19	15	21	18	18
Claude	16	19	14	20	20	19	15	21	20	17
Gemini	17	18	21	22	19	18	22	24	19	18
Perplexity	17	19	22	20	19	18	15	20	15	21

Critical ≤13
Fail 14-15
Caution 15-20
Pass ≥21
High ≥22

61

Results


Figure 2. Platform Safety Dimension Profiles



62

Results

Figure 3. Sycophancy Trajectory: Safety Under Escalating Social Pressure (Question 10)



63

Discussion

- All major consumer AI platforms rely on largely proprietary, black-box algorithms with limited transparency in architecture, training data, reasoning processes, and privacy, despite differences in visible features like citations, reinforcing the importance of pharmacist awareness to help patients navigate their limitations.
- Medication safety performance was inconsistent across AI platforms, with no tool demonstrating uniformly reliable responses across all clinical scenarios.
- Platforms demonstrated distinct safety profiles across dimensions (eg, accuracy, hallucination resistance, bias), with strengths varying by tool—indicating complementary capabilities but no single platform consistently excelling across all medication safety domains.
- Susceptibility to persuasive or authority-based prompts varied across platforms, with some models maintaining safety responses (Perplexity) while others showed declining resistance over repeated interactions (ChatGPT, Claude, Gemini), indicating risk of inconsistent guidance in patient counseling scenarios.

64

Conclusions

- General-purpose patient-facing AI can generate responses to user queries; however, it lacks the ability to verify whether the question is appropriate, the clinical context is complete, or critical patient-specific details have been omitted, potentially limiting the safety and accuracy of its guidance.
- Pharmacists should not be positioned as an opponent to AI but as the human safety net that stress-tests what the AI produced.
- The pharmacist is the only participant who consistently applies clinical knowledge at the level the patient needs — even when the AI demonstrably possesses the same knowledge.

65

Self-Assessment Questions

1. A patient tells you they used an AI chatbot to research their new statin prescription and received detailed information about side effects, but they can't tell you where the information came from. Based on what you know about AI transparency, which of the following statements is most accurate?
 - a) All AI tools provide citations by default, so the information is likely verifiable.
 - b) Source attribution varies significantly by platform; some tools cite nearly all claims while others rarely attribute sources unprompted, so patients may not be able to verify the accuracy of what they've read.
 - c) If an AI tool sounds confident and provides detailed information, the response is likely accurate and based on current clinical evidence.
 - d) If a patient asks an AI follow-up questions, it will automatically retrieve updated or more reliable sources to improve accuracy.

66

Self-Assessment Questions

2. What is the pharmacist's role when patients use AI for medication information?

- a) To verify AI-generated medication information for accuracy, since AI platforms frequently provide incorrect drug interaction data and lack sufficient pharmacological knowledge.
- b) The pharmacist is the only participant who consistently applies clinical knowledge at the level the patient needs; even when the AI demonstrably possesses the same knowledge.
- c) To serve as a backup resource for complex cases only, since AI platforms reliably handle routine medication questions but struggle with multi-drug interactions and narrow therapeutic index drugs.
- d) To redirect patients away from AI platforms entirely, since the inconsistency of AI-generated medication advice makes these tools unsuitable for any patient-facing health information.

67

Shining Light on Hidden Risks: How Pharmacists Can Illuminate Artificial Intelligence Transparency and Protect Public Health

Nicole J. Asal, PharmD, BPCS

nicole_asal@uri.edu

The University of Rhode Island, College of Pharmacy

Nathan Siegel, PharmD

nathan.siegel@communitypharmacyaisolutions.com

Community Pharmacy AI Solutions

Connect with us on
LinkedIn®

68



Continuing Professional Development for Evolving Pharmacy Practice and Regulation

Logan T. Murry, PharmD,
Assistant Director Continuing Pharmacy Education and Continuing Professional Development
Accreditation Council of Pharmacy Education

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)

69

NABP | National Association of Boards of Pharmacy
Poster Presentations Webinar 2026

Continuing Professional Development for Evolving Pharmacy Practice and Regulation

Presenter: Logan T. Murry, PharmD, PhD
Contributor: Dimitra V. Travlos, PharmD, FNAP
Accreditation Council for Pharmacy Education (ACPE)

NABP Virtual Educational Poster Session • 2026

70

Financial Disclosures

Logan T. Murry, PharmD, PhD • Dimitra V. Travlos, PharmD, FNAP

Logan T. Murry and Dimitra V. Travlos declare that they are employees of the Accreditation Council for Pharmacy Education. Logan and Dimitra have no current affiliation or financial arrangement with any organization that may have a direct interest in the subject matter of this CPE activity. All individuals in control of content have no relevant financial relationships with ineligible companies to disclose.

ACPE | Continuing Professional Development

71

Learning Objectives

After viewing this presentation, learners should be able to:

1. Describe the key principles of Continuing Professional Development (CPD) as defined by ACPE.
2. Explain the structure and components of the ACPE CPD accreditation pathway, including the CPD cycle.
3. Recognize how CPD units (CPDUs) differ from traditional continuing pharmacy education (CPE) credit.
4. Identify opportunities to integrate CPD into existing and evolving regulatory models to support learner-centered development and expanded pharmacy practice.

ACPE | Continuing Professional Development

72

Introduction

ACPE defines CPD as *“a self-directed, ongoing, systematic and outcomes-focused approach to lifelong learning that is applied into practice.”¹*

CPD has been shown to increase the impact of continuing pharmacy education (CPE) on student and pharmacist development, with positive benefits observed across:

- Students during experiential education.
- Preceptor development.
- Practicing pharmacists completing continuing education.

The role of CPD has continued to expand internationally and in the US with certification bodies and some states (Iowa, New Mexico) including CPD in the relicensure process.

ACPE | Continuing Professional Development

73

CPD Program Description

Key Milestones


January 2023: ACPE Board of Directors approved principles for CPD program development.

January 2024: Accreditation pathway launched, enabling Providers to award CPD units (CPDUs).

March 2026: CPDUs now appear in CPE Monitor for all CPE Monitor users.

The CPD Cycle

- 1 Reflect
- 2 Plan
- 3 Learn
- 4 Evaluate
- 5 Apply



Up to 2 CPDUs per cycle component; max 10 CPDUs per cycle

ACPE | Continuing Professional Development

74

ACPE CPD Principles

Principle 1 Systematic Planning Providers establish a systematic planning process for CPD development and implementation.	Principle 2 CPD Program Design Program design is based around the CPD cycle components: Reflect, Plan, Learn, Evaluate, Apply, Record/Review.
Principle 3 Assessment of Learner CPD Providers validate and document learner engagement, with formative and summative feedback throughout the cycle.	Principle 4 CPD Program Evaluation Providers conduct structured program evaluation to determine effectiveness and guide ongoing improvement.

ACPE | Continuing Professional Development

75

Accredited Providers and Awarding CPD Units

4 Accredited CPD Programs	40+ Activities Offered Across Programs	100+ CPD Units Awarded to Date	10 Max CPDUs Per Cycle
-------------------------------------	--	--	----------------------------------

Current Accredited CPD Program Providers:

- Dana-Farber Cancer Institute
- ProCE, LLC
- The University of Florida College of Pharmacy
- The University of Texas at Austin College of Pharmacy

As of March 2026, CPDUs appear in CPE Monitor for all users — not just CPE Monitor Plus subscribers.

ACPE | Continuing Professional Development

76

Principles and Applications of CPD

State Boards of Pharmacy

Use CPD for improvement or correction plans after disciplinary action; aligns with standard-of-care regulatory models where pharmacists demonstrate current knowledge and skills. States like Iowa and New Mexico already allow for CPD as a component of the relicensure process.

Practitioners

Increase the amount and impact of continuing education (CE) taken, including application of learning to practice and identification of new learning needs.²

Faculty and Preceptors

Facilitate annual review, promotion and tenure, and preceptor development to improve clinical teaching, communication skills, and educational resource development.³

Students and Residents

Facilitate achievement of learning outcomes and establish foundational lifelong learning habits.⁴

CE Providers

Address specific ACPE commendation criteria related to individual learning plans and CPD for the CE team (eg ACPE C2, C8, C13).

ACPE | Continuing Professional Development

77

Discussion and Conclusions

Providing an accredited CPD program has the potential to facilitate the intentional and cyclical process of learning required for learners to apply knowledge and skills into practice.

State Boards of Pharmacy can use CPD as a component of disciplinary action or in support of standard-of-care regulatory models, with CPDUs available in CPE Monitor to demonstrate participation in self-directed learning.

ACPE | Continuing Professional Development

78

Self-Assessment Question 1

What is the defining feature of Continuing Professional Development (CPD)?

- a. Self-directed, outcomes-focused learning process.
- b. Focus on time spent in educational activities.
- c. Mandatory completion of standardized courses.
- d. Exclusive use of live educational formats.

ACPE | Continuing Professional Development

79

Self-Assessment Question 2

Which of the following is NOT a way that CPD can be implemented by regulatory bodies to support expanded pharmacist practice and evolving regulatory models?

- a. By incorporating CPD into relicensure requirements
- b. By limiting CPD to preceptor development only
- c. By adopting CPD for relicensure to support pharmacists in the Standard-of-Care regulatory model
- d. By including the CPD process in disciplinary or corrective action

ACPE | Continuing Professional Development

80

Self-Assessment Question 3

Which of the following represents the correct sequence of the continuing professional development cycle?

A. Learn → Apply → Reflect → Record/Review → Plan → Evaluate

B. Reflect → Plan → Learn → Evaluate → Apply → Record/Review

C. Plan → Learn → Evaluate → Record/Review → Apply → Reflect

D. Record/Review → Reflect → Learn → Plan → Apply → Evaluate

ACPE | Continuing Professional Development

81

References and Acknowledgments

Acknowledgments

We would like to acknowledge the members of the ACPE CPD Advisory Committee.

Resources

1. Murry LT, et al. Principles for Continuing Professional Development (CPD) Programs: A Statement by the ACPE CPD Advisory Committee. Am J Pharm Educ. 2023;100578.
2. Dopp AL, Moulton JR, Rouse MJ, Trewet CB. A five-state continuing professional development pilot program for practicing pharmacists. Am J Pharm Educ. 2010;74(2).
3. Cooksey K, Mailig M, Kieser M, Martin B, Margolis A. Impact of an online pharmacy precepting-focused CPD program. Curr Pharm Teach Learn. 2023;15(7):673-9.
4. Cooley J, Frederick KD, Larson S. Promoting CPD through a novel CPD advanced pharmacy practice experience. Curr Pharm Teach Learn. 2023;15(1):85-90.
5. Estevez MM, Murry LT, Turner S, Armitstead JA. Pharmacist perceptions of continuing professional development and goal development in a community-health system. Curr Pharm Teach Learn. 2024; 16(12)

ACPE | Continuing Professional Development

82

Thank You

For more information about ACPE CPD, visit: <https://www.acpe-accredit.org/program/continuing-professional-development>

Contact Information

Logan T. Murry, PharmD, PhD
Accreditation Council for Pharmacy Education
lmurry@acpe-accredit.org

Dimitra V. Travlos, PharmD, FNAP
Accreditation Council for Pharmacy Education
dtravlos@acpe-accredit.org

83

Submit Your CPE Claim

1. Claim your CPE credit by signing in to NABP's submission site:
<https://nabp.pharmacy/claimcpe> (case-sensitive)
If you do not have a login for NABP's CPE submission site, you will need to create an account.
2. Click on the "Live CPE" tab
3. Select the webinar from the Live Meetings and Conferences list
4. Enter the session code provided at the end of the webinar
5. Complete the course and speaker evaluations
6. Select the appropriate credit (pharmacist or pharmacy technician)
7. Enter your NABP e-Profile ID and date of birth and certify that the information is correct
8. Click the claim button

Claims must be submitted by noon on August 10, 2026.

NABP does not submit CPE credit claims on participants' behalf. Attendees must follow the steps above by August 10, 2026, in order for the credit to appear in CPE Monitor®.

Copyright © 2026 National Association of Boards of Pharmacy® (NABP®)



NABP® and NABP Foundation® are accredited by the Accreditation Council for Pharmacy Accreditation (ACPE) as providers of continuing pharmacy education (CPE). ACPE provider number: 0205.

1.5 contact hours (0.15 CEU)
0205-0000-26-048-L99-P
0205-0000-26-048-L99-T

The handouts for today's presentation can be found at:
www.nabp.pharmacy/webinar

Questions about submitting your claim?
Please contact CPE@nabp.pharmacy.

NABP®

84